Global Alzheimer’s Disease Treatment Market: Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Alzheimer’s Disease Treatment Market by drug type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), route of administration (Oral, Implants, Others), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Alzheimer’s disease treatment market size was valued at US$ 6.1 Billion in 2020 and is expected to grow US$ 9.05 Billion by 2027 at a CAGR of 5.8% during the forecast period. Alzheimer’s disease is a neurodegenerative disorder that attacks the brain’s nerve cells, or neurons, leading to cell death and degeneration. The most common symptoms of Alzheimer’s disease are memory loss, incognition, disorientation, behavioural changes, personality changes, and trouble in speaking and writing. Alzheimer’s disease (AD) mainly occurs in adults with aging mid-sixties, which leads to 60% to 70% of cases of dementia. The major causes of Alzheimer’s disease are genetic disorders and the disease process associated with plaques and tangles in the brain. The diagnostic test for Alzheimer’s disease includes cognitive testing with medical imaging and blood tests.  Alzheimer’s disease risks can be overcome by mental and physical exercise and avoiding obesity. Alzheimer’s disease treatment market is expected to grow at a significant CAGR due to an increase in the prevalence of Alzheimer’s disease. According to World Health Organisation, escalation of the geriatric population leads to an increase in Alzheimer’s disease cases, which in turn affect the market positively over the forecast period. Apart from this, increase in healthcare spending and R&D investments in the global Alzheimer’s research, expiration of patents, and entry of new generics into the market expected to fuel the growth of the market. Similarly, the discovery of new disease-modifying drugs, and presence of vast last-stage pipeline drugs expected to boost the market over the forecast period. However, the limited number of treatment options for Alzheimer’s disease in the market, challenges in precise diagnosis and even detection of Alzheimer’s disease, and lack of funding from government in developing economies for research might hamper the growth of the market over the forecast period. Moreover, the high degree of research failure and uncertainty within the research and development of drugs might hinder the growth of the Alzheimer’s disease treatment market.

 

Key Development:

 

On May 09, 2022, EISAI completes rolling submission to the U.S. FDA  for Biologics Licence Application (BLA) of LECANEMAB fro early ALZHEIMER’S disease approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. EISAI has requested priority review for the same. Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA during fiscal year 2022.

 

On July 08, 2021, Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution.

Alzheimer’s Disease Treatment Market

MARKET SUMMARY
-
5.8% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.8%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Alzheimer’s Disease Treatment Market

  • Researchers are looking for new ways to treat Alzheimer’s disease to address the Alzheimer’s disease market needs. Currently available drugs help mask the symptoms of Alzheimer’s disease but they do not stop its progression.
  • There are several promising drugs in developmental and testing stage for Alzheimer’s disease, but researchers need more funding of research to ensure that fresh ideas continue to fill the pipeline.
  • In January 2015, Johnson & Johnson partnered with Swiss biopharma AC Immune to develop a therapeutic vaccine for the development of anti-tau Alzheimer’s vaccine
  • In September 2014, Eli Lilly and AstraZeneca came into an alliance to co-develop the partial treatment for Alzheimer’s disease
Market Leaders
  • Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Eisai Pharmaceuticals Co. Ltd. (Japan)
  • Lundbeck A/S (Denmark)
  • Johnson & Johnson Services Inc., (U.S.)
  • AstraZeneca (U.K.)
  • Pfizer Inc. (U.S.)
  • Forest Laboratories (U.S.)
  • Eli Lilly and Company (U.S.)
Alzheimer’s Disease Treatment Market

Drivers and Restraints

Alzheimer’s disease treatment market is in the growing stage with several international players operating in the Alzheimer’s disease treatment market. According to Centres for Disease Control and Prevention (CDC) the global prevalence of Alzheimer’s disease will triple among elderly patients, and the prevalence increases to 13.8 million by 2050. Several drug molecules lost patents and few more expected lose patents in near future, which is expected to crate market opportunity for generic players. Majority of drugs in pipeline failed in the late stage of clinical trials, for instance, Eli Lilly’s solanezumab and Pfizer/Johnson & Johnson’s bapineuzumab have failed to prove the disease-slowing effects in the late-stage of clinical trials.Moreover, In 2014, FDA has approved cholinesterase inhibitors (Exelon, Aricept, and Razadyne) and memantine for the treatment of cognitive symptoms in Alzheimer disease. The other medication is Namzaric (combination of donepezil with memantine) manufactured by Allergan for the treatment of Alzheimer’s disease.


Alzheimer’s Disease Treatment Market Regional Analysis

North America dominates the market

Geographically, the Alzheimer’s disease treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. According to the United Nations Population Fund, the people aged over 60 make up for 12.3% of the world’s population, which is estimated to exceed to almost 22% by 2050, with the increase in geriatric population the market for Alzheimer’s drugs expected to bolster during the forecast period 2017 to 2023. North America contributes the maximum demand for Alzheimer’s drugs. According to the American Alzheimer’s Association, almost 5 Mn adults are suffering from Alzheimer’s disease and due to the increasing aging populations, it may expect to grow in future. Similarly, increasing coverage of Alzheimer’s disease by Medicare, an insurance program encourages more Alzheimer’s patients to seek medical treatment, expected driving market growth. According to Alzheimer’s Association UK, there are 850,000 people with dementia in the UK in 2015 which is expected to increase to approximately 1 Mn during forecasting period which expected to contribute significantly to the overall growth of the European Alzheimer’s disease treatment market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Alzheimer’s Disease Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

  1. Executive summary
  2. Global Alzheimer’s Disease Treatment Market Introduction
    • Global Alzheimer’s Disease Treatment Market– Taxonomy
    • Global Alzheimer’s Disease Treatment Market–Definitions
      • Drug Type
      • Distribution Channel
  1. Global Alzheimer’s Disease Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Alzheimer’s Disease Treatment Market Dynamics – Factors Impact Analysis
    • Global Alzheimer’s Disease Treatment Market– Regulations
      • S
      • Europe
      • Japan
  1. Global Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  2. Global Alzheimer’s Disease Treatment Market, By Drug Type, 2013 – 2017 and Forecast, 2018 – 2024
    • Cholinesterase Inhibitors
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • NMDA Receptor Antagonists
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Alzheimer’s Disease Treatment Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Implants
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Alzheimer’s Disease Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Alzheimer’s Disease Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
  2. North America Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Implants
      • Others
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • North America Alzheimer’s Disease Treatment Market Dynamics – Trends
  3. Europe Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Implants
      • Others
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Europe Alzheimer’s Disease Treatment Market Dynamics – Trends
  4. Asia-Pacific Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Implants
      • Others
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
  • Asia-Pacific Alzheimer’s Disease Treatment Market Dynamics – Trends
  1. Latin America Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Implants
      • Others
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Alzheimer’s Disease Treatment Market Dynamics – Trends
  2. Middle East & Africa Alzheimer’s Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Cholinesterase Inhibitors
      • NMDA Receptor Antagonists
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Implants
      • Others
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Alzheimer’s Disease Treatment Market- Opportunity Analysis Index – By Drug Type, By Surgery, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • MEA Alzheimer’s Disease Treatment Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Hoffmann-La Roche Ltd (Switzerland)
      • Novartis AG (Switzerland)
      • Eisai Pharmaceuticals Co. Ltd. (Japan)
      • Lundbeck A/S (Denmark)
      • Johnson & Johnson Services Inc., (U.S.)
      • AstraZeneca (U.K.)
      • Pfizer Inc. (U.S.)
      • Forest Laboratories (U.S.)
      • Eli Lilly and Company (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Eisai Pharmaceuticals Co. Ltd. (Japan)
  • Lundbeck A/S (Denmark)
  • Johnson & Johnson Services Inc., (U.S.)
  • AstraZeneca (U.K.)
  • Pfizer Inc. (U.S.)
  • Forest Laboratories (U.S.)
  • Eli Lilly and Company (U.S.)

Description

Alzheimer’s disease treatment market size was valued at US$ 6.1 Billion in 2020 and is expected to grow US$ 9.05 Billion by 2027 at a CAGR of 5.8% during the forecast period. Alzheimer’s disease is a neurodegenerative disorder that attacks the brain’s nerve cells, or neurons, leading to cell death and degeneration. The most common symptoms of Alzheimer’s disease are memory loss, incognition, disorientation, behavioural changes, personality changes, and trouble in speaking and writing. Alzheimer’s disease (AD) mainly occurs in adults with aging mid-sixties, which leads to 60% to 70% of cases of dementia. The major causes of Alzheimer’s disease are genetic disorders and the disease process associated with plaques and tangles in the brain. The diagnostic test for Alzheimer’s disease includes cognitive testing with medical imaging and blood tests.  Alzheimer’s disease risks can be overcome by mental and physical exercise and avoiding obesity. Alzheimer’s disease treatment market is expected to grow at a significant CAGR due to an increase in the prevalence of Alzheimer’s disease. According to World Health Organisation, escalation of the geriatric population leads to an increase in Alzheimer’s disease cases, which in turn affect the market positively over the forecast period. Apart from this, increase in healthcare spending and R&D investments in the global Alzheimer’s research, expiration of patents, and entry of new generics into the market expected to fuel the growth of the market. Similarly, the discovery of new disease-modifying drugs, and presence of vast last-stage pipeline drugs expected to boost the market over the forecast period. However, the limited number of treatment options for Alzheimer’s disease in the market, challenges in precise diagnosis and even detection of Alzheimer’s disease, and lack of funding from government in developing economies for research might hamper the growth of the market over the forecast period. Moreover, the high degree of research failure and uncertainty within the research and development of drugs might hinder the growth of the Alzheimer’s disease treatment market.

 

Key Development:

 

On May 09, 2022, EISAI completes rolling submission to the U.S. FDA  for Biologics Licence Application (BLA) of LECANEMAB fro early ALZHEIMER’S disease approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. EISAI has requested priority review for the same. Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA during fiscal year 2022.

 

On July 08, 2021, Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX